Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects
- PMID: 10406241
- DOI: 10.1111/j.1572-0241.1999.01211.x
Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects
Abstract
Objective: In previous studies on rats, we have shown that aspirin (ASA)-induced injury to the gastric mucosa is markedly reduced or completely abolished if ASA is chemically associated with the phospholipid, phosphatidylcholine (PC). We have also shown that the protective effect of PC does not influence the ability of ASA to inhibit mucosal cyclooxygenase (COX) activity in the stomach and other tissues. We therefore sought to assess the effect of PC-associated ASA (ASA/PC) on the gastric mucosa of normal volunteers and to compare the results with the use of ASA alone.
Methods: Sixteen normal healthy subjects were administered ASA or ASA/PC in a randomized, double-blind, crossover study. The subjects received ASA in a dose of 650 mg three times a day for 3 days or an equivalent dose of ASA chemically associated with PC. Endoscopy was performed at baseline and again on the morning of day 4, after the subjects had taken the final dose of the test drug. On both occasions, antral biopsy specimens were obtained for the assessment of mucosal COX activity and prostaglandin concentration.
Results: The number (mean +/- SD) of gastric erosions seen with the ASA/PC formulation was significantly less than when ASA was used alone (8.7 +/- 10.7 vs 2.9 +/- 4.3; p < 0.025). A similar trend was seen in the duodenum but the difference was statistically not significant. The antral mucosal COX activity, as well as the level of prostaglandin 6-keto PGF1alpha, were reduced significantly (80-88%) and to a similar extent by both ASA and ASA/PC.
Conclusions: The present study shows that acute aspirin-induced damage to the gastric mucosa can be reduced by chemically associating ASA with PC. The mechanism of mucosal protection provided by this compound is not related to any alteration in the ability of ASA to inhibit mucosal COX activity. We believe this protection is attributable to the maintenance of the defensive hydrophobic barrier of the gastric mucosa.
Similar articles
-
Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection.Aliment Pharmacol Ther. 2006 Apr 15;23(8):1225-33. doi: 10.1111/j.1365-2036.2006.02856.x. Aliment Pharmacol Ther. 2006. PMID: 16611284 Clinical Trial.
-
Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase.J Physiol Pharmacol. 2006 Nov;57 Suppl 5:125-36. J Physiol Pharmacol. 2006. PMID: 17218764 Clinical Trial.
-
Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.Am J Gastroenterol. 2001 Jun;96(6):1751-7. doi: 10.1111/j.1572-0241.2001.03928.x. Am J Gastroenterol. 2001. PMID: 11419825 Clinical Trial.
-
Role of prostaglandins in gastroprotection and gastric adaptation.J Physiol Pharmacol. 2005 Sep;56 Suppl 5:33-55. J Physiol Pharmacol. 2005. PMID: 16247188 Review.
-
Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins.J Physiol Pharmacol. 2008 Aug;59 Suppl 2:89-102. J Physiol Pharmacol. 2008. PMID: 18812631 Review.
Cited by
-
Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage.J Gastroenterol. 2015 Jun;50(6):614-25. doi: 10.1007/s00535-014-1034-z. Epub 2015 Jan 13. J Gastroenterol. 2015. PMID: 25578017 Review.
-
Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety.Gut Liver. 2013 Jan;7(1):7-15. doi: 10.5009/gnl.2013.7.1.7. Epub 2012 Nov 13. Gut Liver. 2013. PMID: 23423874 Free PMC article.
-
Phospholipids and lipid-based formulations in oral drug delivery.Pharm Res. 2010 Aug;27(8):1469-86. doi: 10.1007/s11095-010-0130-x. Epub 2010 Apr 22. Pharm Res. 2010. PMID: 20411409 Review.
-
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation.Clin Pharmacokinet. 2022 Apr;61(4):465-479. doi: 10.1007/s40262-021-01090-2. Epub 2022 Jan 20. Clin Pharmacokinet. 2022. PMID: 35060092 Free PMC article. Review.
-
Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates.Osteoporos Int. 2011 Jun;22(6):1717-23. doi: 10.1007/s00198-010-1374-3. Epub 2010 Sep 3. Osteoporos Int. 2011. PMID: 21069296
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources